Results 21 to 30 of about 2,233 (157)
Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma
, 2021 Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine of the interleukin-2 (IL-2) cytokine family with both homeostatic and inflammatory properties in the human organism.
Yao, Y. +3 more
core +1 more source
Tezepelumab in severe asthma: a profile of its use
, 2023 Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of ...
Yahiya Y. Syed (4897507)
core +1 more source
Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma
, 2023 Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades.
Hiroki Kabata +3 more
core +1 more source
Tezepelumab in Adults with Uncontrolled Asthma
New England Journal of Medicine, 2017 In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose ...
Jonathan, Corren +6 more
openaire +2 more sources
[Tezepelumab: a new option for the treatment of severe asthma]
Revista medica del Instituto Mexicano del Seguro Social, 2023 Resumen En Latinoamérica, el asma es un problema de salud pública con un impacto importante tanto para los pacientes como para los sistemas de salud. El mayor entendimiento de la fisiopatología y el reconocimiento del papel central que tiene la inflamación en la severidad del asma ha favorecido el desarrollo de anticuerpos monoclonales que tienen como ...
Maldonado-Ríos, Valente Armando +3 more
openaire +3 more sources
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Chronic rhinosinusitis (CRS) represents a spectrum of inflammatory endotypes, driven by distinct T helper (Th) immune responses. The high rate of recurrent disease despite appropriate medical and surgical interventions highlights the need for improved characterization beyond the traditional type 2 and non‐type 2 phenotypes to better
Liyona Kampel +9 more
wiley +1 more source
, 2023 International audienceWhat is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab.
Corren, Jonathan +12 more
core +1 more source
Tezepelumab : En ny effektiv behandling för patienter med svår, okontrollerad astma?
, 2023 Bakgrund Astma är en kronisk sjukdom som försvårar lungfunktion och påverkar individer hela livet. Orsakerna för astma är olika mellan olika individer, men sjukdomen har liknande symtom.
Khouly, Rama
core +3 more sources
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Biologic treatments were introduced for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2019. Treatment algorithms for medically refractory CRSwNP remain open, with patients choosing among surgery, biologics, or both. Real‐world utilization of surgery and biologics remains incompletely characterized.
Stephanie Shintani Smith +5 more
wiley +1 more source
, 2023 Tanya M Laidlaw1,2 *, Andrew Menzies-Gow3 *, Scott Caveney,4 Joseph K Han,5 Nicole Martin,6,7 Elliot Israel,8 Jason K Lee,9,10 Jean-Pierre Llanos,11 Neil Martin,12,13 Ayman Megally,14 Bhavini Parikh,14 Sylvia Vong,15 Tobias Welte,16 Jonathan ...
Llanos JP +12 more
core